These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 19637402)

  • 1. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada.
    Varas-Lorenzo C; Castellsague J; Stang MR; Perez-Gutthann S; Aguado J; Rodriguez LA
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1016-25. PubMed ID: 19718696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.
    Velentgas P; West W; Cannuscio CC; Watson DJ; Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):641-52. PubMed ID: 16392153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
    García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A
    Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
    Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
    Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F; Suissa S; Garbe E
    Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ; Weideman RA; Kelly KC; Brilakis ES; Banerjee S; Cunningham F; Harford WV; Kazi S; Little BB; Cryer B
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):252-60. PubMed ID: 18787084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke.
    Roumie CL; Mitchel EF; Kaltenbach L; Arbogast PG; Gideon P; Griffin MR
    Stroke; 2008 Jul; 39(7):2037-45. PubMed ID: 18436878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.